Company Overview of Pall Corporation
Pall Corporation manufactures and markets filtration, separation, and purification products; and integrated systems solutions worldwide. Its Life Sciences segment provides technologies that facilitate the process of drug discovery, development, regulatory validation, and production, which are used in the research laboratories, pharmaceutical, biotechnology, and food and beverage industries, as well as in hospitals. It offers medical products to control the spread of infections in hospitals; cell therapy products; and filtration and purification technologies, associated hardware, and engineered systems for the development and commercialization of drugs, plasma, and vaccines. This segment also...
25 Harbor Park Drive
Port Washington, NY 11050
Founded in 1946
Key Executives for Pall Corporation
Group Vice President and President of Pall Life Sciences
President of Pall Industrial
Compensation as of Fiscal Year 2017.
Pall Corporation Key Developments
Orgenesis Ltd. and Pall Corporation Partnership Accomplishes Project Financed by the BIRD Foundation
Dec 11 17
Orgenesis Ltd. announced that Orgenesis and Pall Corporation have completed their joint development program supported by the Israel-U.S. Binational Industrial Research and Development Foundation. Orgenesis is focused on developing an innovative autologous cell-based therapy for the treatment of diabetes.
Pall Corporation Presents at 4th Op-Ex Russia & CIS 2017, Nov-15-2017
Nov 11 17
Pall Corporation Presents at 4th Op-Ex Russia & CIS 2017, Nov-15-2017 . Venue: Swissotel Resort Sochi Kamelia, Sochi, Russia. Speakers: Andrey Chernyshev, Head of Refining Department.
Wuxi Biologics and Pall Corporation Establish Joint Continuous Bioprocess Laboratory
Nov 3 17
WuXi Biologics and its partner Pall Corporation established a joint laboratory to develop full continuous processing for the manufacturing of monoclonal antibodies (mAb). The 3-year project started with the continuous operation of individual processes and will gradually be expanded to downstream processing development and production. The joint laboratory will serve WuXi Biologics' customers worldwide in an attempt to significantly reduce mAb drugs' manufacturing costs and benefit patients around the world. An opening ceremony for the WuXi Biologics and Pall joint laboratory was held by the two parties on November 2, 2017. The joint laboratory, constructed with Pall Life Sciences' unique CadenceTM Integrated Continuous Bioprocess System and integrated with its single-use technology platform, ensures process flexibility, facilitates switches between processes and avoids cross-contamination, thereby enabling pharmaceutical companies to reduce the manufacturing space required at a facility and to reduce cost. After years of intensive efforts on technological development, WuXi Biologics has developed high-yielding cell lines and laboratory-scale continuous processes, significantly increasing the expression of some mAbs to up to equivalent of 40-50 g/L in the traditional fed-batch process, which is approximately 10 times more productive than the typical fed-batch process.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|